MIR4457: A Drug Target / Disease Biomarker (G100616235)

MIR4457: A Drug Target / Disease Biomarker

MIR4457 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells.

One of the unique features of MIR4457 is its ability to interact with various drugs, including small molecules, peptides, and proteins. This interactivity makes MIR4457 an attractive target for drug development, particularly for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, MIR4457 has also been shown to be a valuable biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The research on MIR4457 began in the late 1990s, when scientists identified its presence in various tissues of the brain. Since then, researchers have used a variety of techniques to study its function and potential as a drug target.

One of the key findings of these studies is that MIR4457 is involved in the formation and maintenance of the blood-brain barrier, which is a specialized barrier that separates the brain from the rest of the body. This barrier is critical for the safe delivery of drugs to the brain and is thought to play a role in the development of neurodegenerative diseases.

In addition to its role in the blood-brain barrier, MIR4457 is also involved in the regulation of cell signaling pathways that are important for brain development and function. This involves the regulation of the activity of several signaling pathways, including the TGF-β pathway, which is involved in the development and maintenance of tissues and organs, and the NF-kappa-B pathway, which is involved in inflammation and immune responses.

These findings have important implications for the development of drugs that target MIR4457 and are being studied in clinical trials. By blocking the activity of MIR4457, researchers hope to reduce the formation of neurodegenerate structures and improve brain function in individuals with neurodegenerative diseases.

Another potential application of MIR4457 is its use as a biomarker for cancer. Several studies have shown that MIR4457 is expressed in a variety of cancer types, including breast, ovarian, and prostate cancer. This makes it an attractive target for the development of diagnostic tools and therapies for these cancers.

In addition to its potential as a drug and biomarker, MIR4457 is also of interest to researchers as a potential structural protein. Its unique structure and the fact that it can interact with a variety of drugs and biomarkers make it an attractive target for studies on protein-protein interactions and the regulation of signaling pathways.

In conclusion, MIR4457 is a protein that has significant potential as a drug target and biomarker for a variety of diseases. Its unique structure and the fact that it is involved in several important signaling pathways make it an attractive target for research into the treatment of neurodegenerative diseases and cancer. Further research is needed to fully understand the role of MIR4457 in these diseases and to develop effective therapies.

Protein Name: MicroRNA 4457

The "MIR4457 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4457 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4458 | MIR4458HG | MIR4463 | MIR4465 | MIR4466 | MIR4467 | MIR4468 | MIR4469 | MIR4470 | MIR4472-1 | MIR4472-2 | MIR4474 | MIR4475 | MIR4476 | MIR4478 | MIR4479 | MIR448 | MIR4481 | MIR4482 | MIR4483 | MIR4484 | MIR4485 | MIR4486 | MIR4487 | MIR4488 | MIR4489 | MIR4491 | MIR4492 | MIR4493 | MIR4496 | MIR4497 | MIR4498 | MIR4499 | MIR449A | MIR449B | MIR449C | MIR4500 | MIR4500HG | MIR4501 | MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2 | MIR4509-3 | MIR450A1 | MIR450A2 | MIR450B | MIR4510 | MIR4511 | MIR4512 | MIR4513 | MIR4514 | MIR4516 | MIR4519 | MIR451A | MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2